Cost Effectiveness of DCISionRT for Guiding Treatment of Ductal Carcinoma in Situ

The DCISionRT test estimates the risk of an ipsilateral breast event (IBE) in patients with ductal carcinoma in situ (DCIS) as well as the benefit of adjuvant radiation therapy (RT). We determined the cost-effectiveness of DCISionRT using a Markov model simulating 10-year outcomes for 60-year-old wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Raldow, Ann C, Sher, David, Chen, Aileen B, Punglia, Rinaa S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083239/
https://www.ncbi.nlm.nih.gov/pubmed/32211582
http://dx.doi.org/10.1093/jncics/pkaa004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083239/
https://www.ncbi.nlm.nih.gov/pubmed/32211582
http://dx.doi.org/10.1093/jncics/pkaa004

Ejemplares similares